Drug Approval | December 29, 2021
JB Chemicals and Pharmaceuticals to launch molnupiravir next month
It will be marketed under the brand name Molunamax
It will be marketed under the brand name Molunamax
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
